Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of AZD1722 in End-Stage Renal Disease Patients on Hemodialysis
NCT01764854 is registered in ClinicalTrials.gov with Ardelyx as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of AZD1722 in End-Stage Renal Disease Patients on Hemodialysis
- Lead sponsor
- Ardelyx
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2013
- Completion date
- October 31, 2013
- Enrollment
- 88 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
chronic kidney disease stage 5, end stage renal disease, esrd